News for Cardiff Oncology, Inc. (CRDF)

PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/

Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cash and Short-term Investments: $91.7 million as of December 31, 2024.Capital Raise: $40 million completed in December 2024.Cash Used in Operating Activities:

Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsKiki Patel - Investor Relations,...

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 16% and 11.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (”œmCRC”) clinical trial (CRDF-004)

Cardiff Oncology (CRDF) announces securities offerings worth up to $400M. Learn more about their plans for stocks, debt, and warrants.

Cardiff Oncology Inc (CRDF) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $0.09 million, and the earning

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. ( CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop nove

**media[546123]**

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the

Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising results, with improved response rates and potential financial benefits. Read more here.

Cardiff Oncology's promising Phase 2 trial data for Onvansertib in colorectal cancer may lead to accelerated FDA approval, making it a strong buy. Click to read.

Cardiff Oncology (CRDF) stock rallied 46% Tuesday after it reported positive data for its oncology drug onvansertib and priced a $40M registered direct offering. Read more here.

North Carolina-based Chimerix, Inc. (CMRX) is up over 163 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

**media[488268]**

**media[488034,488035]**